Caplacizumab-yhdp

Category: Blood Clotting (Hemostasis)



Caplacizumab-yhdp Overview

Caplacizumab (ALX-0081) (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2] This drug was developed by Ablynx NV.[3] On 31 August 2018 it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".[4] It is an anti-von Willebrand...

Read more Caplacizumab-yhdp Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Caplacizumab

Recent Caplacizumab-yhdp Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Caplacizumab-yhdp
  • Injection: 11mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Caplacizumab-yhdp or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA